Bispecific antibodies for AD treatment are being tested in early-stage clinical trials (Phase I/II), which evaluate drug safety together with pharmacokinetics and biomarkers, such as amyloid PET, CSF Aβ42, plasma p-tau217, and glial fibrillary acidic protein (GFAP) [63]. Here, GFAP is linked to Alzheimer disease.